Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

ATAI Life Sciences NV Stock Research

ATAI

1.36USD-0.05(-3.55%)Delayedas of 20 Sep 2023, 11:36 am
Watchlist

Market Summary

USD1.36-0.05
Delayedas of 20 Sep 2023, 11:36 am
-3.55%

ATAI Alerts

  • 1 major insider buys recently.

ATAI Stock Price

ATAI RSI Chart

ATAI Valuation

Market Cap

234.1M

Price/Earnings (Trailing)

-1.61

Price/Sales (Trailing)

863.74

EV/EBITDA

-0.8

Price/Free Cashflow

-2.27

ATAI Price/Sales (Trailing)

ATAI Profitability

EBT Margin

-50712.64%

Return on Equity

-62.77%

Return on Assets

-52.95%

Free Cashflow Yield

-44.06%

ATAI Fundamentals

ATAI Revenue

Revenue (TTM)

271.0K

Revenue Y/Y

35.43%

Revenue Q/Q

364.86%

ATAI Earnings

Earnings (TTM)

-145.1M

Earnings Y/Y

9.77%

Earnings Q/Q

0.28%

Price Action

52 Week Range

1.143.70
(Low)(High)

Last 7 days

-2.1%

Last 30 days

-10.8%

Last 90 days

-13.5%

Trailing 12 Months

-61.9%

ATAI Financial Health

Current Ratio

13.43

Debt/Equity

0.06

Debt/Cashflow

-6.87

ATAI Investor Care

Shares Dilution (1Y)

7.82%

Diluted EPS (TTM)

-0.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for ATAI

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-13
Brand Florian
bought
57,968
1.4492
40,000
see remarks
2023-03-29
Brand Florian
bought
103,558
1.4794
70,000
see remarks
2023-03-29
Apeiron Investment Group Ltd.
bought
1,600,440
1.318
1,214,300
-
2022-04-29
Apeiron Investment Group Ltd.
bought
97,801
4.4658
21,900
-
2022-04-28
Apeiron Investment Group Ltd.
bought
154,689
4.4579
34,700
-
2022-04-27
Apeiron Investment Group Ltd.
bought
91,939
4.6427
19,803
-
2022-04-26
Apeiron Investment Group Ltd.
bought
216,628
4.6882
46,207
-
2022-04-25
Apeiron Investment Group Ltd.
bought
42,842
4.781
8,961
-
2022-04-22
Apeiron Investment Group Ltd.
bought
254,962
4.827
52,820
-
2022-04-21
Apeiron Investment Group Ltd.
bought
340,040
4.9505
68,688
-

1–10 of 27

Which funds bought or sold ATAI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-08-25
Gould Capital, LLC
added
66.67
1,585
4,300
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
0.21
-9,439
188,374
-%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-57.94
-3,750
2,497
-%
2023-08-16
Global Frontier Investments LLC
sold off
-
-
-
-%
2023-08-15
GOLDMAN SACHS GROUP INC
reduced
-36.15
-69,224
106,800
-%
2023-08-15
Belpointe Asset Management LLC
sold off
-100
-272
-
-%
2023-08-15
MONETA GROUP INVESTMENT ADVISORS LLC
unchanged
-
-1,147
21,923
-%
2023-08-15
Cornerstone Planning Group LLC
new
-
688
688
-%
2023-08-15
WELLS FARGO & COMPANY/MN
unchanged
-
-6.00
17.00
-%
2023-08-14
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
sold off
-100
-1,814
-
-%

1–10 of 47

Latest Funds Activity

Are funds buying ATAI calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ATAI
No. of Funds

Schedule 13G FIlings of ATAI Life Sciences

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 01, 2022
galaxy group funding eci u llc
6.7%
10,796,736
SC 13G
Feb 10, 2022
apeiron investment group ltd.
19.7%
32,059,504
SC 13G

Recent SEC filings of ATAI Life Sciences

View All Filings
Date Filed Form Type Document
Sep 14, 2023
4
Insider Trading
Sep 07, 2023
SC 13D/A
13D - Major Acquisition
Sep 05, 2023
4
Insider Trading
Aug 31, 2023
8-K
Current Report
Aug 10, 2023
8-K
Current Report
Aug 10, 2023
10-Q
Quarterly Report

ATAI Life Sciences News

Nasdaq
Tenet Healthcare (THC) & Oracle Unite to Improve Efficiency.
Nasdaq,
24 hours ago
StreetInsider.com
Form 424B3 COMPASS Pathways plc.
StreetInsider.com,
26 hours ago
Best Stocks
Proactive Investors USA
Pharmaceutical Technology
Pharmaceutical Technology

Returns for ATAI

Cumulative Returns on ATAI

Risks for ATAI

What is the probability of a big loss on ATAI?

95.0%


Probability that ATAI Life Sciences stock will be more than 20% underwater in next one year

93.3%


Probability that ATAI Life Sciences stock will be more than 30% underwater in next one year.

81.5%


Probability that ATAI Life Sciences stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ATAI drawdown profile look like?

Y-axis is the maximum loss one would have experienced if ATAI Life Sciences was unfortunately bought at previous high price.

Drawdowns

Financials for ATAI Life Sciences

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22021Q42021Q32021Q22021Q1
Revenue7.5%271,000252,000233,0006,947,33313,661,66720,376,00030,068,00039,760,00079,520,000
Operating Expenses-2.4%141,335,000144,828,000145,020,000152,821,000148,001,000156,181,000198,013,000171,772,000116,278,000
  S&GA Expenses-1.0%65,674,00066,337,00070,350,00080,499,00081,344,00092,745,000138,853,000122,917,00088,437,000
EBITDA100.0%--133,756,000-134,506,000-144,296,000-137,679,000-136,554,000-179,230,000-174,072,000-
EBITDA Margin100.0%--497-577--6.76-6.70-4.47-2.91-
Interest Expenses105.8%2,560,0001,244,000508,000------
Earnings Before Taxes-0.6%-137,269,000-136,417,000-135,182,000-144,440,000-137,780,000-136,601,000-179,262,000-174,116,000-113,961,000
EBT Margin100.0%--507-580--6.76-6.70-4.47-2.91-
Net Income2.4%-145,075,000-148,651,000-152,385,000-196,251,000-193,522,000-167,808,000-165,525,000-217,562,000-185,458,000
Net Income Margin100.0%--552-654--9.50-8.24-4.13-3.64-
Free Cashflow100.0%--102,589,000-105,240,000-95,154,000-94,583,000-63,419,000-49,122,000-26,635,000-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22020Q4
Assets-9.7%254281305343349384414484506112
  Current Assets-9.4%243268287317324349375442458100
    Cash Equivalents-24.1%14118619114384.0012436243045497.00
  Net PPE-6.4%1.001.001.001.000.000.000.000.000.000.00
Liabilities-5.3%38.0040.0040.0047.0029.0029.0028.0021.0021.0016.00
  Current Liabilities-10.2%18.0020.0020.0026.0022.0022.0021.0015.0014.0012.00
  Long Term Debt0.6%15.0015.0015.0015.00------
Shareholder's Equity-10.3%21323726128931234637745347591.00
  Retained Earnings-6.1%-576-543-510-465-431-394-357-268-237-189
  Additional Paid-In Capital1.1%792783774762746735725709691262
Shares Outstanding0%166166166166154154161151132115
Minority Interest-19.1%3.004.005.007.008.008.009.0010.0010.005.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q2
Cashflow From Operations-0.7%-102-101-104-94.47-94.54-70.71-63.25-48.95-26.29-37.58-20.77-21.78-18.21
  Share Based Compensation-1.8%40.0041.0042.0044.0045.0073.0063.0011510590.0067.009.000.00
Cashflow From Investing-2.6%140144-86.85-215-282-292-81.28-36.51-41.27-17.28-28.27-21.50-38.06
Cashflow From Financing-9.1%19.0021.0021.0023.008.0037941049050417411372.0026.00

ATAI Income Statement

2023-06-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
License revenue$ 172,000$ 170,000$ 209,000$ 170,000
Operating expenses:    
Research and development15,476,00017,949,00034,757,00033,409,000
Acquisition of In Process Research and Development0357,0000357,000
General and administrative16,558,00017,221,00030,529,00035,203,000
Total operating expenses32,034,00035,527,00065,286,00068,969,000
Loss from operations(31,862,000)(35,357,000)(65,077,000)(68,799,000)
Other income (expense), net:    
Interest income303,000117,000579,000215,000
Interest expense(658,000)0(1,280,000)0
Change in fair value of contingent consideration liability - related parties76,00095,000111,00095,000
Change in Fair Value of Warrant Liability053,000053,000
Change in fair value of securities carried at fair value526,000(584,000)1,490,000(1,324,000)
Foreign exchange gain (loss), net(9,000)4,882,000(846,000)7,045,000
Other income (expense), net34,00012,000209,00012,000
Total other income (expense), net204,0004,551,000263,0006,072,000
Loss before income taxes(31,658,000)(30,806,000)(64,814,000)(62,727,000)
Provision for income taxes(185,000)(51,000)(351,000)(92,000)
Losses from investments in equity method investees, net of tax(1,928,000)(6,652,000)(2,961,000)(12,248,000)
Net loss(33,771,000)(37,509,000)(68,126,000)(75,067,000)
Net loss attributable to noncontrolling interests(729,000)(891,000)(1,948,000)(1,580,000)
Net loss attributable to ATAI Life Sciences N.V. stockholders$ (33,042,000)$ (36,618,000)$ (66,178,000)$ (73,487,000)
Net loss per share attributable to ATAI Life Sciences N.V. stockholders - basic$ (0.21)$ (0.24)$ (0.42)$ (0.48)
Net loss per share attributable to ATAI Life Sciences N.V. stockholders - diluted$ (0.21)$ (0.24)$ (0.42)$ (0.48)
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. Stockholders - basic155,792,490153,971,202155,793,323153,751,456
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. stockholders - diluted155,792,490153,971,202155,793,323153,751,456

ATAI Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 141,090$ 190,613
Securities carried at fair value86,40282,496
Prepaid expenses and other current assets6,25714,036
Short term notes receivable - related parties, net9,0210
Total current assets242,770287,145
Property and equipment, net1,043928
Operating lease right-of-use asset, net1,367226
Other investments3,9916,755
Long term notes receivable - related parties, net1,1577,262
Notes Receivable, Related Parties, Noncurrent1,1577,262
Other assets3,2673,125
Total assets253,595305,441
Current liabilities:  
Accounts payable3,8592,399
Accrued liabilities12,85517,306
Current portion of lease liability322180
Other current liabilities89012
Total current liabilities17,92619,897
Non-current portion of contingent consideration liability - related parties842953
Non-current portion of lease liability1,09544
Convertible promissory notes - related parties, net of discounts and deferred issuance costs420415
Long-term debt, net14,86814,702
Other liabilities2,8073,664
Total liabilities37,95839,675
Commitments and contingencies (Note 16)
Stockholders' equity:  
Common stock,0.10 par value ($0.12 par value at June 30, 2023 and December 31, 2022, respectively); 750,000,000 shares authorized at June 30, 2023 and December 31, 2022, respectively; 166,010,476 and 165,935,914 shares issued and outstanding at June 30, 2023 and December 31, 2022 respectively18,57118,562
Additional paid-in capital791,688774,092
Share subscription receivable0(24)
Accumulated other comprehensive loss(20,818)(21,702)
Adjustment to accumulated deficit (pursuant to adoption of ASU 2016-13)(576,891)(510,188)
Total stockholders' equity attributable to ATAI Life Sciences N.V. stockholders212,550260,740
Noncontrolling interests3,0875,026
Total stockholders' equity215,637265,766
Total liabilities and stockholders' equity$ 253,595$ 305,441
Florian Brand
80
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.